458566-84-2

Usage

Uses

Used in Pharmaceutical Industry:
4,4-Difluorocyclohexanamine is used as a key intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique structure allows for the creation of molecules with specific properties that can target and treat a range of medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 4,4-Difluorocyclohexanamine is utilized as a precursor in the synthesis of pesticides and other crop protection agents. Its incorporation into these compounds can enhance their effectiveness in protecting crops from pests and diseases, thereby supporting agricultural productivity.
Used in Organic Synthesis:
4,4-Difluorocyclohexanamine is employed as a building block in organic synthesis for the construction of a wide array of organic compounds. Its presence in these compounds can impart specific chemical and physical properties, making it a valuable component in the synthesis of specialty chemicals and other complex organic molecules.
Used in Research and Development:
As a valuable tool in medicinal and agricultural research, 4,4-Difluorocyclohexanamine is used in the development of new chemical entities and the study of their biological activities. Its unique structure and reactivity make it an important compound in exploring novel chemical spaces and advancing scientific understanding in these fields.
Safety Precautions:
Given its moderately hazardous nature, 4,4-Difluorocyclohexanamine must be handled with appropriate safety measures. This includes the use of personal protective equipment, proper storage conditions, and adherence to safety protocols to minimize risks associated with its use in various applications.

Upstream product

• 122665-97-8 4,4-difluorocyclohexanecarboxylic acid 
• 179321-49-4 N-(tert-butoxycarbonyl)-4-aminocyclohexanone 
• 810675-56-0 C₁₄H₁₇F₂NO₂ 
• 675112-67-1 tert-butyl (4,4-difluorocyclohexyl)carbamate 

Downstream Products

• 810675-56-0 C₁₄H₁₇F₂NO₂ 
• 1198103-23-9 2-(4,4-difluorocyclohexyl)-N-[1-(5-methyl-2-thienyl)ethyl]-3-oxoisoindoline-1-carboxamide 
• 1202409-18-4 N-(4,4-difluorocyclohexyl)-6-(3-fluorophenyl)nicotinamide 
• 1449736-73-5 N-(4,4-difluorocyclohexyl)-8-nitroquinazolin-4-amine 
• 1374296-88-4 2-((2,6-dichlorophenyl)amino)-N-(4,4-difluorocyclohexyl)-7,7-dimethyl-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide 

Relevant academic research and scientific papers

Decarboxylative Amination: Diazirines as Single and Double Electrophilic Nitrogen Transfer Reagents

The ubiquity of nitrogen-containing small molecules in medicine necessitates the continued search for improved methods for C-N bond formation. Electrophilic amination often requires a disparate toolkit of reagents whose selection depends on the specific structure and functionality of the substrate to be aminated. Further, many of these reagents are challenging to handle, engage in undesired side reactions, and function only within a narrow scope. Here we report the use of diazirines as practical reagents for the decarboxylative amination of simple and complex redox-active esters. The diaziridines thus produced are readily diversifiable to amines, hydrazines, and nitrogen-containing heterocycles in one step. The reaction has also been applied in fluorous phase synthesis with a perfluorinated diazirine.

ASK1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

The present disclosure relates to a compound as shown in formula (II), a tautomer or a pharmaceutically acceptable salt thereof, and disclosed is the use thereof in preparing a drug for treating an ASK1-associated disease.

COMPOUNDS AND THERAPEUTIC USES THEREOF

The invention relates to compounds, pharmaceutical compositions, and uses thereof, including therapeutic uses thereof, such as methods useful for treating cancer.

2-SUBSTITUED 5, 6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATOR.

The present invention relates to 5, 6-diaryl-pyrazine-2-carboxamide and- 2-ester derivatives and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them. The compounds are cannabinoid receptor 1 (CB1) modulators.

GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS

A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein.

Substituted quinazolinone compounds

A variety of low molecular weight, guanidino-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure IA, IB, or IC where the values of the variab

SUBSTITUTED QUINAZOLINONE COMPOUNDS

A variety of low molecular weight, guanidino-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure of Formulas (IA), (IB), or (IC): where the v